Table 3.
Antimicrobial resistance of Pseudomonas aeruginosa clinical isolates obtained from patients at a hospital center in China
| Antimicrobial | %Resistance
|
P-value | |||||
|---|---|---|---|---|---|---|---|
| 2012 (n=370) | 2013 (n=344) | 2014 (n=406) | 2015 (n=414) | 2016 (n=486) | 2017 (n=221) | ||
| Amikacin | 27.9 | 25 | 39 | 28 | 11.5 | 3.6 | <0.001 |
| Ceftazidime | 22.5 | 17 | 23 | 28 | 10.5 | 8.6 | <0.001 |
| Ciprofloxacin | 22.8 | 14 | 16 | 18 | 19 | 13.6 | <0.001 |
| Colistin | 2.4 | 0 | 0 | 0 | 0 | 0 | NS |
| Gentamicin | 34.8 | 35 | 45 | 25 | 21.5 | 11.4 | <0.001 |
| Meropenem | 19.5 | 21 | 23 | 22 | 17 | 15.2 | <0.001 |
| Piperacillin/tazobactam | 21.3 | 18 | 7 | 15 | 8.5 | 2.9 | <0.001 |
| Cefoperazone/sulbactam | 7.6 | 5.8 | 8.2 | 11.4 | 7.5 | 6.5 | <0.001 |
| Imipenem | 12 | 14 | 28 | 30 | 15.5 | 17.1 | <0.001 |
| Tigecycline | 0 | 0 | 1 | 2 | 2 | 2 | NS |
Abbreviation: NS, not significant.